GLP‑1 weight‑loss drugs: diet essential for lasting results

Glucagon‑like peptide‑1 (GLP‑1) receptor agonists such as semaglutide, tirzepatide, liraglutide and the newer oral agents semaglutide tablets and orforglipron have transformed obesity treatment, delivering average weight losses of 11‑14 % over 12‑16 months and, in some cases, 15‑20 % or more. The medications work by slowing gastric emptying, reducing appetite and improving blood‑sugar control, but they commonly cause gastrointestinal side effects like nausea, vomiting, diarrhea or constipation.

Clinical experts and commercial programs stress that sustained success depends on complementary nutritional support. Recommendations include prioritising high‑protein foods (lean meats, fish, eggs, Greek yogurt, beans, tofu), staying well‑hydrated, consuming high‑fiber cereals, and planning meals to avoid missed nutrition when appetite is suppressed. Support services such as Kroger Health’s GLP‑1 Complete Support and diet‑focused guidance from GoodRx aim to help patients manage affordability, side‑effect mitigation and lifestyle changes.

Regulatory updates note that oral semaglutide has received European Union approval for obesity, while orforglipron is approved in the United States and under review by the European Medicines Agency. Ongoing research highlights that diet and exercise remain critical to maintain weight loss after drug discontinuation and to prevent muscle‑mass loss.